Neuropace, Inc. (NPCE) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Neuropace, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.385 -- 00:00:05.728 Hello, everyone. Thank you for joining us and welcome to the Neuropace Q2 2026 00:00:05.728 -- 00:00:11.392 earnings call. After today's prepared remarks, we will host a question and answer session. 00:00:11.392 -- 00:00:16.595 If you would like to ask a question, please press star 1 to raise your hand. 00:00:16.595 -- 00:00:20.558 To withdraw your question, press star 1 again. 00:00:20.558 -- 00:00:24.881 I will now hand the conference over to Scott Schaefer, Head of Investor Relations. 00:00:24.881 -- 00:00:27.135 Scott, please go ahead. 00:00:27.135 -- 00:00:32.399 Thank you, operator, and welcome to Neuropace's second quarter 2026 earnings conference 00:00:32.399 -- 00:00:37.523 call. Our agenda begins with Joel Becker, Neuropace's chief executive officer, 00:00:37.523 -- 00:00:42.107 who will summarize our recent performance and strategic progress, followed by a detailed 00:00:42.107 -- 00:00:46.610 financial review and outlook for Patrick Williams, our chief financial officer. 00:00:46.610 -- 00:00:50.980 Following our prepared remarks, we will open the call for questions. 00:00:50.980 -- 00:00:55.383 Before we begin, I would like to remind you that certain statements made on today's call 00:00:55.383 -- 00:01:01.468 may constitute forward-looking statements within the meaning of federal securities laws. 00:01:01.468 -- 00:01:05.611 These statements include, among others, comments regarding our financial outlook for 00:01:05.611 -- 00:01:07.032 2026, 00:01:07.032 -- 00:01:12.096 our commercial strategy, clinical and product development initiatives, regulatory 00:01:12.096 -- 00:01:17.600 matters including our PMA supplement for expanded indication into idiopathic generalized 00:01:17.600 -- 00:01:24.497 epilepsy, or IGE, and ...